Accessibility Menu
Arcus Biosciences logo

Arcus Biosciences(NYSE) RCUS

Market Cap$3.84BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)+78%
5 Year+2%
1 Year+186%
1 Month+6%
Premium Feature
Moneyball Superscore
55/100
$31.10
+3.25%
+0.98Today
Arcus Biosciences last closing stock price
MetricPriceDate
Last closeUSD 30.122026-08-24
Arcus Biosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.89%USD 29.562026-08-17
1 month+5.98%USD 28.422026-07-24
3 month+24.82%USD 24.132026-05-26
Year to date+26.4%USD 23.832025-12-31
1 year+186.04%USD 10.532025-08-22
3 year+33.33%USD 22.592023-08-25
5 year+2.28%USD 29.452021-08-25
Since inception+78.47%USD 17.002018-03-15

Arcus Biosciences Financials at a Glance

Market Cap

$3.84BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$117.00M

Net Income (TTM)

-$452.00M

EPS (TTM)

-$3.90

P/E Ratio

-7.71

Dividend

$0.00

Beta (Volatility)

1.55 (High)

Price

$31.10

Volume

159,831.009

Open

$30.11

Previous Close

$30.12

Daily Range

$30.11 - $31.44

52-Week Range

$10.07 - $31.74

Estimated Earnings Date

Oct 27, 2026

RCUS News

SellAlert-Blue.png

An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run

Jonathan PoncianoJul 13, 2026
SellAlert-Purple.png

Arcus Biosciences President Sells $2 Million as Stock Delivers 48% Annual Return

Sara AppinoJan 5, 2026
a scientist uses a pipette to work with medical samples..jpg

Arcus Biosciences President Sells $2 Million in Stock Under Trading Plan

Jonathan PoncianoNov 2, 2025
Foolcom-Featured.png

Arcus (RCUS) Q2 Revenue Jumps 310%

Motley Fool Markets TeamAug 6, 2025
pole vault

Why Arcus Biosciences Stock Vaulted Higher in November

George Budwell, PhDDec 9, 2021
chalk

Why Arcus Biosciences Stock Is On Fire Today

George Budwell, PhDNov 18, 2021
scientist-biotech-comparing-test-tubes-getty

Why Arcus Biosciences' Big Reveal Wasn't Very Exciting

Cory RenauerJun 25, 2021
life-science-pro-making-selection-getty

Here's Why Arcus Biosciences Stock Is Rising Today

Cory RenauerJun 24, 2021
Page 1

RCUS: Motley Fool Moneyball Superscore

55

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Arcus Biosciences

Arcus Biosciences, Inc. creates new medicines to help people fight cancer. These therapies target specific parts of the body to stop tumors. The company focuses on making better treatments for serious diseases.

Fighting Cancer With Targeted Molecules

  • HIF-2a Inhibitor: Casdatifan, an oral medicine designed to block proteins that help kidney cancer grow.
  • Anti-TIGIT Antibody: Domvanalimab, an immune therapy currently in Phase 2 and Phase 3 trials for lung and stomach cancers.
  • Anti-PD-1 Antibody: Zimberelimab, an investigational drug that helps the immune system attack cancer cells.
  • CD73 Inhibitor: Quemliclustat, a treatment targeting specific enzymes that can help tumors spread.

Clinical Milestones and Strategic Shifts

  • Announced a clinical trial collaboration with Summit Therapeutics in July 2026 to evaluate casdatifan.
  • Entered a clinical supply agreement with AVEO Oncology in July 2026 to test drug combinations.
  • Formed a collaboration with Bristol Myers Squibb in June 2026 to study casdatifan.
  • Saw Gilead's option rights for several early-stage programs end on July 14, 2026.
  • Raised $438 million in total gross proceeds during 2025 through two separate stock offerings.

What Makes Arcus Unique

Arcus uses internal discovery tools to create small-molecule therapies for cancer and immune diseases. The company manages development through strategic partnerships that share costs and clinical risks.

A Look at the Numbers

  • Total revenues were $41 million for the three months ended June 30, 2026, down 74% year over year.
  • Research and development expenses were $113 million for the three-month period ended June 30, 2026, down 19% year over year.
  • Net loss was $91 million for the three months ended June 30, 2026.
  • Market capitalization was $3.5 billion according to recent market data.
  • Cash and investments are expected to fund planned operations until at least the second half of 2028.

Bottom Line

Arcus has evolved from an early-stage research firm to a developer of multiple late-stage cancer treatments. Its adaptability is shown by its focus on high-potential programs like casdatifan while streamlining other operations.

AI Generated • Aug 6, 2026

Industry

Biotechnology

Sector

Health Care

Employees

601

CEO

Terry J. Rosen, PhD

Website

arcusbio.com

Headquarters

Hayward, CA 94545, US

RCUS Financials

Key Financial Metrics (TTM)

Gross Margin

94.02%

Operating Margin

-415.38%

Net Income Margin

-386.32%

Return on Equity

-87.98%

Return on Capital

-51.95%

Return on Assets

-48.92%

Earnings Yield

-12.97%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.84BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

127.33M

Volume

159.83K

Avg. Volume

1.32M

Financials (TTM)

Gross Profit

$110.00M

Operating Income

-$486.00M

EBITDA

-$419.00M

Operating Cash Flow

-$474.00M

Capital Expenditure

-$1.00M

Free Cash Flow

-$475.00M

Cash & ST Invst.

$702.00M

Total Debt

$114.00M

Arcus Biosciences Performance Analysis

Arcus Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 112,000,000-70.7%
20232023-12-31USD 117,000,0004.5%
20242024-12-31USD 258,000,000120.5%
20252025-12-31USD 247,000,000-4.3%
Arcus Biosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-83.8%
Q42025-12-3126.9%
Q12026-03-31-48.5%
Q22026-06-30141.2%
Arcus Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -3.71N/A
20232023-12-31USD -4.1511.9%
20242024-12-31USD -3.14-24.3%
20252025-12-31USD -3.294.6%
Arcus Biosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-1487.5%
Q42025-12-3127.6%
Q12026-03-31-10.9%
Q22026-06-3029.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$41.00M

-74.4%

Gross Profit

$41.00M

-74.4%

Gross Margin

100.00%

N/A

Market Cap

$3.84BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.38M

N/A

Employees

601

N/A

Net Income

-$91.00M

-1037.5%

EBITDA

-$85.00M

-2225.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$702.00M

-22.9%

Total Debt

$114.00M

+4.6%

Accounts Receivable

$36.00M

+80.0%

Inventory

$0.00

N/A

Long Term Debt

$101.00M

+4.1%

Short Term Debt

$13.00M

+8.3%

Return on Assets

-48.92%

N/A

Return on Invested Capital

-66.94%

N/A

Free Cash Flow

-$119.00M

+10.5%

Operating Cash Flow

-$119.00M

+10.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DNLIDenali Therapeutics Inc.
$25.05+3.49%
BEAMBeam Therapeutics Inc.
$30.82+8.77%
VRDNViridian Therapeutics, Inc.
$24.37+1.46%
OCULOcular Therapeutix, Inc.
$11.06+2.55%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$211.54+0.01%
INTCIntel
$88.03+0.01%
BITOProShares Trust - ProShares Bitcoin ETF
$10.73+0.01%
IBITiShares Bitcoin Trust
$45.05+0.01%

Questions About RCUS

What is the current price of Arcus Biosciences?

Arcus Biosciences is trading at $31.18 per share.

What is the 52-week range for Arcus Biosciences?

Over the past 52 weeks, Arcus Biosciences has traded between $10.07 and $31.74.

How much debt does Arcus Biosciences have?

As of the most recent reporting period, Arcus Biosciences reported total debt of $114.00M.

How much cash does Arcus Biosciences have on hand?

Arcus Biosciences reported $150.00M in cash and cash equivalents in its most recent financial results.

What is Arcus Biosciences’s dividend yield?

Arcus Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services